The 9th World Congress on Targeting Microbiota 2022: Towards Clinical Revolution will be held on October 19-21 in Paris and Online.
Targeting Microbiota 2022 Congress aims to introduce the most recent advances microbiota in health and diseases, as well as all the recent innovations and therapeutical strategies. The Chairmen of the scientific committee: Marvin Edeas, Institut Cochin, INSERM, Université de Paris, France, and Peter Konturek, Teaching Hospital of the University of Jena, Germany, stated: “In order to have a clearer picture on the strategic role of Microbiota, this year, we will put together many complementary talks and topics, controversies and clinical advances. We will allocate more time to the discussion, mainly about the way to manage the huge marketing speed compared to science of microbiota.”
Among the topics that the ISM will cover during the congress:
- Microbiota Dysbiosis in Diseases: Recent Advances
- Microbiota Metabolites: State of the Art & Perspective
- Microbiota, Slimming & Weight Loss: Science or Marketing?
- Personalized Nutrition and Microbiota
- Microbiota in Mineral Water & Hot Springs: Unexplored Science
- Role of Microbiota in Drugs Metabolism: Towards Personalized Medicine
- Targeting Microbiota Dysbiosis: Strategies to Manipulate the Microbiome & Microbiota
- Brain, Behavior, Ageing and Microbiota
- Microbiota Innovation, Challenges & Sprints
- Discussion: Microbiota World – Between Science and Marketing
Among the Targeting Microbiota 2022 hot topics:
Pierre Déchelotte, Rouen Normandy University, France, will discuss the recent discoveries on the Probiotic Strain H. alvei HA4597 for Weight Loss.
The Beneficial Effects of Natural Mineral Waters on Intestinal Inflammation and the Mucosa-Associated Microbiota will be discussed exclusively by Nicolas Barnich, Université Clermont Auvergne, France, to further understand the role of different microbiota profiles in water sources.
Targeting Microbiota 2022 will especially focus on the extracellular vesicles with Fermin I. Milagro, University of Navarra, Spain. He will present his research on Gut Microbiota-Derived Extracellular Vesicles on Obesity, Diabetes and Metabolism.
Annalisa Terranegra, Sidra Medical and Research Center, Qatar, will chair a session on Personalized Nutrition & Microbiota. She will present her most recent findings on Precision Nutrition to Modulate Gut Microbiota in Reproductive Health and Pregnancy.
François Leullier, Université de Lyon, France, will share his recent studies on Microbial Influence on Linear Growth. His approaches aim at identifying both the bacterial and host genetic and metabolic networks required to sustain their mutualistic relationship.
Stephen Lindemann, Purdue University, USA, will discuss the Manipulation of Fiber Polysaccharide Structure to Alter Targeting to Gut Microbiota.
Andrés Moya, University of València, Spain, will present recent studies on the Healthy Human Gut Microbiota in a Mediterranean Cohort.
Among the microbiota innovations which will be presented: Bertrand Routy, University of Montreal Hospital, Canada, will explain how it is possible to target the microbiota in order to treat cancer, by shifting the microbiome toward a more diverse and beneficial bacterial composition and promoting response to therapy.
Nathan Price, Thorne HealthTech, USA, will discuss the importance of interpreting microbiomes and introduce a new microbiome sample collection technology.
Carmen González-Bosch, Universitat de València, Spain, will present the role of short chain fatty acids in redox signaling in health and in disease.
The future of microbiota medicine will also be discussed by Peter C. Konturek, president of ISM, and Marvin Edeas, chairman of the scientific committee. They will present and discuss the latest findings on FMT research and strategies to target microbiota - mitochondria.
André Schmidt, University of Basel, Switzerland, will introduce the use of Probiotics and FMT as Add-on Therapies for Depression.
Frank Scheer, Harvard Medical School, USA, will present a proof-of-principle demonstration of endogenous circadian system and circadian misalignment effects on human oral microbiota. His findings provide translational relevance to individuals typically exposed to circadian misalignment, including night shift workers and frequent flyers.
Lei Dai, Shenzhen Institute of Advanced Technology, China, will highlight the Understanding the Heterogeneity of Host-associated Microbial Communities.
On October 19, a workshop on The Evaluation & Modulation of Gut microbiota will be dedicated to the presentation of all the methods of evaluating microbiota, as well as the development of pre, pro and post-biotics with a view to understand how these formulations may be at the heart of rebalancing and strengthen the microbiome.
You can also submit your abstract before October 10.
For more information about Targeting Microbiota Congress, visit the ISM conference site or follow the meeting hashtag #TargetingMicrobiota.
About the International Society of Microbiota (ISM):
ISM was born in 2013 after the transformation of the Task Force Mitochondria-Microbiota to a larger group gathering all actors and experts working in the field of microbiota. The idea is to bring a new level of thinking and understanding of microbiota science out of the classical existing point of view. The science of gut and microbiota is a dynamic field, with a huge evolution and affected by multi factors. ISM will bring this new dynamic point of view to accelerate the credible translation of this science into real benefit for the consumer. ISM also encourages the communication and interaction among researchers, physicians, nutritionists, industrials, food technology and strategic marketing managers through a global microbiota network, especially during its annual world meeting. After its last meeting, the ISM published an exhaustive review on Microbiota Medicine: Towards Clinical Revolution in the Journal of Translational Medicine.